To assess the tumor-suppressive potential of apelin-dm, mice with subcutaneously injected CT-26 and MC-38 cells were treated intraperitoneally with apelin-dm (30 mg/kg), apelin receptor antagonist ML221 or a saline vehicle control (Fig. 5A). Here, APLNR is linked to neoplasm.